Xintela receives Notice of Allowance from USPTO for the treatment of brain tumors

Lund, Sweden, January 7, 2021 – Xintela today announces that the US Patent and Trademark Office (USPTO) has issued a Notice of Allowance for the Company’s patent application covering targeted antibody treatment of tumors of the central nervous system (CNS). Xintela’s patent application 15/550,837 in the USA protects the use of the target molecule integrin […]

Xintela submits manufacturing license application

Lund, Sweden, 21 December 2020 – Xintela announces today that the company has submitted its application to the Swedish Medical Products Agency for a license to produce cell therapy products, also known as Advanced Therapy Medicinal Products (ATMPs), for clinical studies. Xintela has developed and patented the stem cell product platform XSTEM® and built its […]

Xintela recruits Jeffrey Abbey to Targinta

Lund, Sweden, 14 December 2020 -Xintela AB (publ) announces that Jeffrey Abbey has been recruited as a Senior Management Advisor to support further development of the wholly owned subsidiary Targinta. Mr. Abbey has more than 20 years of experience in the biopharmaceutical industry and has spent much of his career focused on the development of […]

Arbitral award rendered in favour of Xintela in dispute with former underwriters

Lund, Sweden, 4 December 2020 -Xintela AB (publ) announces that the arbitral tribunal today has rendered an arbitral award in the dispute between Xintela and four former underwriters. The arbitral award dismisses the claim for payment brought by the underwriters against Xintela in its entirety. The arbitral award concerns the dispute that arose in connection […]

Xintela Board recommends Maarten de Château as new Board member

Lund, Sweden, 3 December 2020 -Xintela AB (publ) announces that Maarten de Château has accepted an invitation to join the Xintela Board of Directors. The Xintela Board will recommend that shareholders formally appoint Maarten at the next shareholders meeting. In the meantime, Maarten will be adjoined to future Board meetings. Maarten de Château is currently […]

Xintela publishes interim report for the third quarter of 2020

Summary of the interim reportThe “Company” or “Xintela” refers to Xintela AB (publ), corporate registration number 556780-3480. First nine months of the year (1 Jan 2020-30 Sep 2020)· Net sales amounted to TSEK 0 (3).· Loss before tax totalled TSEK 24,922 (loss: 28,081).· Loss per share* was SEK 0.43 (loss: 0.71).· At 30 September 2020, […]

Xintela Board recommends Lars Hedbys as new Board member

Lund, Sweden, 12 November 2020 -Xintela AB (publ) announces that Lars Hedbys has accepted an invitation to join the Xintela Board of Directors.  The Xintela Board will recommend that shareholders formally appoint Lars at the next shareholders meeting. In the meantime, Lars will be adjoined to future Board meetings. Lars Hedbys (born 1957) has significant […]

Newsletter November 2020

Dear shareholders, Xintela is targeting several important milestones in the remainder of 2020 and 2021, which are the result of years of strategic, goal-oriented efforts in stem-cell and cancer treatment projects. In the summary below, I present updates on the status of Xintela’s projects and of the company’s strategy and future milestones, in both the […]

Status report of Xintela published

Lund, Sweden, 30 October 2020 – Xintela announces that a status report of the company has been published by Biostock, that contains both Biostock’s own analysis and information provided by Xintela. Read the analysis through the below link.https://www.biostock.se/en/status-report-xintela-integrins-marking-the-future/ Xintela AB (publ)Evy Lundgren-Åkerlund, CEOTel: +46 46 275 65 00Email: evy@xintela.seMedicon Village223 81 Lund, Swedenwww.xintela.se About XintelaXintela […]